[HTML][HTML] Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline
S Pfeifer, S Butts, D Dumesic, G Fossum, C Gracia… - Fertility and sterility, 2016 - Elsevier
Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a
guideline - ScienceDirect Skip to main contentSkip to article Elsevier logo Journals & Books …
guideline - ScienceDirect Skip to main contentSkip to article Elsevier logo Journals & Books …
Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology
HG Al‐Inany, MA Youssef, RO Ayeleke… - Cochrane Database …, 2016 - cochranelibrary.com
Background Gonadotrophin‐releasing hormone (GnRH) antagonists can be used to prevent
a luteinizing hormone (LH) surge during controlled ovarian hyperstimulation (COH) without …
a luteinizing hormone (LH) surge during controlled ovarian hyperstimulation (COH) without …
[HTML][HTML] The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients …
L Engmann, A DiLuigi, D Schmidt, J Nulsen, D Maier… - Fertility and sterility, 2008 - Elsevier
OBJECTIVE: To determine whether there are any differences in the incidence of ovarian
hyperstimulation syndrome (OHSS) and implantation rates in high-risk patients undergoing …
hyperstimulation syndrome (OHSS) and implantation rates in high-risk patients undergoing …
[HTML][HTML] Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles
EG Papanikolaou, C Pozzobon, EM Kolibianakis… - Fertility and sterility, 2006 - Elsevier
OBJECTIVE: To determine the incidence of ovarian hyperstimulation syndrome (OHSS) in a
large series of GnRH antagonist–stimulated cycles and to assess the predictive value of E2 …
large series of GnRH antagonist–stimulated cycles and to assess the predictive value of E2 …
Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures
MA Aboulghar, RT Mansour - Human reproduction update, 2003 - academic.oup.com
The aim of this review was to summarize previously published classifications for ovarian
hyperstimulation syndrome (OHSS), as well as to analyse the available methods for …
hyperstimulation syndrome (OHSS), as well as to analyse the available methods for …
Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone
JB Engel, AV Schally - Nature clinical practice Endocrinology & …, 2007 - nature.com
This article reviews the clinical uses of agonists and antagonists of luteinizing-hormone-
releasing hormone (LHRH), also known as gonadotropin-releasing hormone. In particular …
releasing hormone (LHRH), also known as gonadotropin-releasing hormone. In particular …
The use of GnRH antagonists in ovarian stimulation
F Olivennes, JS Cunha-Filho, R Fanchin… - Human reproduction …, 2002 - academic.oup.com
GnRH antagonists induce a rapid decrease in LH and FSH, preventing and interrupting LH
surges. Their properties do not require a desensitization period, and this allows their use in …
surges. Their properties do not require a desensitization period, and this allows their use in …
Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol: meta-analysis
M Ludwig, A Katalinic, K Diedrich - Archives of Gynecology and Obstetrics, 2001 - Springer
The use of GnRH antagonists has revolutionized ovarian stimulation for assisted
reproduction. Two GnRH antagonists are clinically available, namely, cetrorelix and …
reproduction. Two GnRH antagonists are clinically available, namely, cetrorelix and …
[HTML][HTML] Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing …
DE Reichman, L Zakarin, K Chao, L Meyer, OK Davis… - Fertility and sterility, 2014 - Elsevier
Objective To identify risk factors for breakthrough LH surge despite GnRH antagonist (GnRH-
ant) suppression in IVF cycles. Design Case-control study. Setting Academic medical center …
ant) suppression in IVF cycles. Design Case-control study. Setting Academic medical center …
Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study
M Ludwig, A Katalinic, C Banz, AK Schröder… - Human …, 2002 - academic.oup.com
INTRODUCTION: This study was performed to evaluate whether a tailored approach to the
administration of the GnRH antagonist cetrorelix acetate according to follicular size leads to …
administration of the GnRH antagonist cetrorelix acetate according to follicular size leads to …